Jason Carroll

MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom.

3i Plc operates as an private equity firm and provides investment advice. The company was founded on July 21, 1945 and is headquartered in London, the United Kingdom.

Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom.

Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK.

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom.

Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU.

Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom.

Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002.

Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.

Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.

Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom.

Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom.

OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom.

Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.

Syncona LLP operates as a healthcare investment company. It invests in companies which focus on gene therapy, cell therapy and patient stratification technologies. The company was founded on October 19, 2012 and is headquartered in London, the United Kingdom.

Syncona Investment Management Ltd. (Syncona) is the asset management subsidiary of Syncona Ltd. in Great Britain. Headquartered in London, the firm was co-founded by Martin Murphy alongside The Wellcome Trust. Syncona is focused on founding, building and funding a portfolio of global leaders in life science.

Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland.

Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom.

Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY.

Part of Syncona Ltd., Syncona Discovery Ltd. is a British company that provides investment services. The company is based in London, UK. Syncona Discovery was founded in 2013.

Macomics Ltd. engages in research and experimental development on biotechnology. The company was founded by Jeffrey William Pollard and Luca Cassetta on November 6, 2018 and is headquartered in Edinburgh, the United Kingdom.

Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom.